LPM3770164 sustained release tablet

DRUG3 trials

Sponsors

Luye Pharma Group Ltd.

Conditions

Huntington DiseaseTardive Dyskinesia

Phase 1

A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects

CompletedNCT05238701

Luye Pharma Group Ltd.Huntington Disease, Tardive Dyskinesia

Start: 2022-02-25End: 2023-11-04Updated: 2024-01-29

Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects

CompletedNCT06216054

Luye Pharma Group Ltd.Huntington Disease, Tardive Dyskinesia

Start: 2023-12-19End: 2024-07-29Updated: 2024-12-12

Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets

CompletedNCT06474650

Luye Pharma Group Ltd.Huntington Disease, Tardive Dyskinesia

Start: 2024-07-31End: 2024-09-25Updated: 2024-12-12